Bone Therapeutics Completes Recruitment in PREOB Phase III Trial

Bone Therapeutics completed recruitment of 44 treated patients required for planned interim analysis of a Phase III trial for PREOB® autologous bone cell therapy in the treatment of osteonecrosis of the hip.

Results from one-year follow-up are expected in 3Q18, and if strong efficacy is documented, recruitment could be terminated...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us